{"url_path":"/sec/dmiiu/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2040475/0001213900-26-056651-index.html","accession_number":"0001213900-26-056651","cik":"0002040475","ticker":"DMII","issuer_name":"Drugs Made In America Acquisition II Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2040475/0001213900-26-056651-index.html","primary_entity_key":"0002040475","primary_entity_name":"Drugs Made In America Acquisition II Corp."},"word_count":1024,"has_tables":true,"body_markdown":"dmiiu-20260331\n\nhttp://fasb.org/srt/2026#ChiefExecutiveOfficerMember\n\nQ1\nfalse\n0002040475\n--12-31\n\n0002040475\n\n2026-01-01\n2026-03-31\n\n0002040475\n\nus-gaap:SubsequentEventMember\nus-gaap:CommonStockMember\n\n2026-04-22\n\n0002040475\n\nus-gaap:SubsequentEventMember\n\n2026-04-22\n\n0002040475\n\nus-gaap:SubsequentEventMember\nus-gaap:CommonStockMember\nsrt:MaximumMember\n\n2026-04-22\n\n0002040475\n\nus-gaap:SubsequentEventMember\nus-gaap:CommonStockMember\nsrt:MinimumMember\n\n2026-04-22\n\n0002040475\n\n2025-01-01\n2025-03-31\n\n0002040475\n\n2025-12-31\n\n0002040475\n\n2026-03-31\n\n0002040475\n\nus-gaap:FairValueInputsLevel1Member\n\n2025-12-31\n\n0002040475\n\nus-gaap:FairValueInputsLevel1Member\n\n2026-03-31\n\n0002040475\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0002040475\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\nus-gaap:OverAllotmentOptionMember\ndmiiu:UnderwritingAgreementMember\n\n2026-03-31\n\n0002040475\n\nus-gaap:OverAllotmentOptionMember\ndmiiu:UnderwritingAgreementMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\nus-gaap:IPOMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\nus-gaap:OverAllotmentOptionMember\ndmiiu:UnderwritingAgreementMember\n\n2025-09-24\n2025-09-24\n\n0002040475\n\n2025-09-24\n2025-09-24\n\n0002040475\n\n2026-03-30\n2026-03-30\n\n0002040475\n\nus-gaap:BridgeLoanMember\n\n2026-03-30\n\n0002040475\n\n2026-03-11\n2026-03-11\n\n0002040475\n\n2026-03-11\n\n0002040475\n\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0002040475\n\ndmiiu:SponsorMember\n\n2025-09-26\n2025-12-31\n\n0002040475\n\nus-gaap:IPOMember\n\n2025-12-31\n\n0002040475\n\nus-gaap:IPOMember\n\n2025-09-26\n\n0002040475\n\n2025-09-29\n\n0002040475\n\nus-gaap:IPOMember\n\n2026-03-31\n\n0002040475\n\nus-gaap:RelatedPartyMember\nus-gaap:CommercialPaperMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\nus-gaap:RelatedPartyMember\nus-gaap:CommercialPaperMember\n\n2024-09-05\n\n0002040475\n\ndmiiu:ConsultingAgreementMember\n\n2025-12-31\n\n0002040475\n\ndmiiu:ConsultingAgreementMember\n\n2026-03-31\n\n0002040475\n\ndmiiu:ConsultingAgreementMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\nus-gaap:CommonStockMember\ndmiiu:AdministrativeSupportAgreementMember\n\n2025-11-17\n\n0002040475\n\n2025-11-17\n2025-11-17\n\n0002040475\n\ndmiiu:ConsultingAgreementMember\n\n2025-11-17\n2025-11-17\n\n0002040475\n\ndmiiu:AdministrativeSupportAgreementMember\n\n2025-12-31\n\n0002040475\n\ndmiiu:AdministrativeSupportAgreementMember\n\n2026-03-31\n\n0002040475\n\ndmiiu:AdministrativeSupportAgreementMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\ndmiiu:AdministrativeSupportAgreementMember\n\n2025-01-01\n2025-03-31\n\n0002040475\n\ndmiiu:AdministrativeSupportAgreementMember\n\n2025-09-24\n2025-09-24\n\n0002040475\n\ndmiiu:FounderShares1Member\n\n2026-03-31\n\n0002040475\n\ndmiiu:FounderShares1Member\n\n2026-01-01\n2026-03-31\n\n0002040475\n\ndmiiu:FounderShares1Member\n\n2024-09-11\n2024-09-11\n\n0002040475\n\nus-gaap:OverAllotmentOptionMember\n\n2024-09-11\n\n0002040475\n\nus-gaap:CommonStockMember\ndmiiu:SponsorMember\ndmiiu:FounderShares1Member\n\n2024-09-11\n\n0002040475\n\nus-gaap:OverAllotmentOptionMember\ndmiiu:FounderShares1Member\n\n2024-09-11\n2024-09-11\n\n0002040475\n\nus-gaap:CommonStockMember\ndmiiu:SponsorMember\ndmiiu:FounderShares1Member\n\n2025-05-01\n2025-05-31\n\n0002040475\n\ndmiiu:SponsorMember\ndmiiu:FounderShares1Member\n\n2025-05-01\n2025-05-31\n\n0002040475\n\nus-gaap:CommonStockMember\ndmiiu:SponsorMember\n\n2025-02-01\n2025-02-28\n\n0002040475\n\nus-gaap:CommonStockMember\ndmiiu:FounderShares1Member\n\n2024-09-11\n\n0002040475\n\nus-gaap:CommonStockMember\ndmiiu:SponsorMember\ndmiiu:FounderShares1Member\n\n2024-09-11\n2024-09-11\n\n0002040475\n\nus-gaap:PrivatePlacementMember\ndmiiu:CantorMember\n\n2025-09-26\n2025-09-26\n\n0002040475\n\nus-gaap:PrivatePlacementMember\ndmiiu:SponsorMember\n\n2025-09-26\n2025-09-26\n\n0002040475\n\nus-gaap:PrivatePlacementMember\n\n2025-09-26\n2025-09-26\n\n0002040475\n\nus-gaap:PrivatePlacementMember\n\n2025-09-26\n\n0002040475\n\nus-gaap:OverAllotmentOptionMember\n\n2025-09-26\n2025-09-26\n\n0002040475\n\nus-gaap:IPOMember\n\n2025-09-26\n2025-09-26\n\n0002040475\n\nus-gaap:OverAllotmentOptionMember\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\ndmiiu:NonRedeemableOrdinaryShareMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\ndmiiu:RedeemableOrdinaryShareMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\n2025-01-01\n2025-12-31\n\n0002040475\n\ndmiiu:ReserveForCurrentExpectedCreditLossesMember\n\n2025-01-01\n2025-12-31\n\n0002040475\n\ndmiiu:ReserveForCurrentExpectedCreditLossesMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\ndmiiu:TrustAccountMember\n\n2026-03-31\n\n0002040475\n\ndmiiu:PublicSharesMember\n\n2026-03-31\n\n0002040475\n\n2025-09-26\n\n0002040475\n\n2025-09-26\n2025-09-26\n\n0002040475\n\nus-gaap:PrivatePlacementMember\ndmiiu:CantorMember\n\n2025-09-26\n2025-09-26\n\n0002040475\n\nus-gaap:PrivatePlacementMember\ndmiiu:SponsorMember\n\n2025-09-26\n2025-09-26\n\n0002040475\n\nus-gaap:OverAllotmentOptionMember\n\n2025-09-26\n\n0002040475\n\n2025-03-31\n\n0002040475\n\n2024-12-31\n\n0002040475\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0002040475\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0002040475\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0002040475\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0002040475\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0002040475\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0002040475\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0002040475\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0002040475\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0002040475\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0002040475\n\ndmiiu:FounderSharesMember\n\n2025-05-31\n2025-05-31\n\n0002040475\n\nus-gaap:CommonStockMember\n\n2025-05-31\n2025-05-31\n\n0002040475\n\n2025-02-28\n2025-02-28\n\n0002040475\n\nus-gaap:OverAllotmentOptionMember\nus-gaap:CommonStockMember\n\n2025-11-08\n2025-11-08\n\n0002040475\n\ndmiiu:NonRedeemableOrdinaryShareMember\n\n2025-01-01\n2025-03-31\n\n0002040475\n\n2026-05-14\n\n0002040475\n\ndmiiu:RightMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\ndmiiu:UnitsMember\n\n2026-01-01\n2026-03-31\n\n0002040475\n\ndmiiu:RedeemableOrdinaryShareMember\n\n2025-01-01\n2025-03-31\n\n0002040475\n\nus-gaap:CommercialPaperMember\n\n2026-03-31\n\n0002040475\n\nus-gaap:CommercialPaperMember\n\n2025-12-31\n\n0002040475\n\ndmiiu:SponsorMember\n\n2026-03-31\n\n0002040475\n\ndmiiu:SponsorMember\n\n2025-12-31\n\n0002040475\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0002040475\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0002040475\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0002040475\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\nxbrli:shares\n\niso4217:USD\n\ndmiiu:Segments\n\nxbrli:pure\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\nFORM 10-Q\n\n \n\n(Mark One)\n\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the quarterly period ended March 31, 2026\n\n \n\n☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the transition period from _______________\nto _______________\n\n \n\nCommission File Number: 001-42863\n\n \n\nDRUGS MADE IN AMERICA ACQUISITION II CORP.\n\n(Exact name of registrant as specified in its charter)\n\n \n\nCayman Islands 98-1815624\n\n(State or other jurisdiction of\n\nincorporation or organization)\n \n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n420 Lexington Avenue, Suite 1402\n\nNew York, New York 10170\n\n(Address of principal executive offices, including zip code)\n\n \n\n(917) 982-4565\n\n(Registrant’s telephone number, including area code)\n\n \n\nN/A\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\nTitle of each class\n \nTrading Symbol(s)\n \nName of each exchange on which registered\n\nUnits, each consisting of one Ordinary Share, par value $0.0001 per share, and one Right to receive one-tenth (1/10) of an Ordinary Share DMIIU The Nasdaq Stock Market LLC\n\nOrdinary Shares DMII The Nasdaq Stock Market LLC\n\nRights DMIIR The Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate by check mark whether\nthe registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging\ngrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting\ncompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\n☐\nLarge accelerated filer\n☐\nAccelerated filer\n\n☒Non-accelerated filer☒Smaller reporting company\n\n  ☒Emerging growth company\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐\n\n \n\nAs of May 14, 2026, there were 63,700,000 ordinary shares outstanding (inclusive of shares included in outstanding units).\n\n \n\n \n\n \n\n \n\n \n\nDRUGS MADE IN AMERICA ACQUISITION II CORP.\n\n \n\nTABLE OF CONTENTS\n\n \n\n \nPage\n\n[Part I – Financial Information](#a_001)\n1\n\n[Item 1. Financial Statements](#a_002)\n1\n\n[Balance Sheets as of March 31, 2026 and December 31, 2025 (Unaudited)](#a_003)\n1\n\n[Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (Unaudited)](#a_004)\n2\n\n[Statements of Changes in Shareholders’ Deficit for the Three Months Ended March 31, 2026 and 2025 (Unaudited)](#a_005)\n3\n\n[Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)](#a_006)\n4\n\n[Notes to Financial Statements (Unaudited)](#a_007)\n5\n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#a_019)\n18\n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#a_020)\n21\n\n[Item 4. Controls and Procedures](#a_021)\n21\n\n[Part II – Other Information](#a_008)\n22\n\n[Item 1. Legal Proceedings](#a_009)\n22\n\n[Item 1A. Risk Factors](#a_010)\n22\n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#a_013)\n22\n\n[Item 3. Defaults Upon Senior Securities](#a_014)\n22\n\n[Item 4. Mine Safety Disclosures](#a_015)\n23\n\n[Item 5. Other Information](#a_016)\n23\n\n[Item 6. Exhibits](#a_017)\n23\n\n[Signatures](#a_018)\n24\n\n \n\ni\n\n \n\n  \n\nPART I – FINANCIAL INFORMATION"}